Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report third quarter 2019 financial results on Tuesday, November 5, 2019, after the close of the market.
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report third quarter 2019 financial results on Tuesday, November 5, 2019, after the close of the market.
Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on November 5, 2019, to discuss third quarter financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing the following:
US domestic callers: (877) 556-5248
Outside US callers: (720) 545-0029
Please reference Conference ID: 2178018
A live webcast of the conference call will be available online from the Investor Relations page of the Company’s website at Events & Presentations. The link will not be active until 1:45 p.m. PT / 4:45 p.m. ET on November 5, 2019.
After the live webcast, the call will be archived on Fluidigm’s Investor Relations page at investors.fluidigm.com. In addition, a telephone replay of the teleconference will be available approximately 90 minutes after the end of the call.
The replay dial-in numbers are:
US domestic callers: (855) 859-2056
Outside US: (404) 537-3406
Please reference Conference ID: 2178018
The telephone replay will be available until November 12.
About Fluidigm
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Contact:
Agnes Lee
Vice President, Investor Relations
Fluidigm Corporation
650 416 7423
agnes.lee@fluidigm.com
